Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.

BMC cancer - 20 Jan 2026

Li Feng, Zhang Chaoqi, Huang Luyu, Wang Ziming, Ye Guanchao, Gu Zhuoyu, Qi Yu

Abstract excerpt

BACKGROUND: Adjuvant targeted therapy represents the standard of care for patients with resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Neoadjuvant therapy can improve surgical and survival outcomes. This study aimed to compare the effectiveness of neoadjuvant immunochemotherapy (NICT) and neoadjuvant targeted therapy plus chemotherapy (NTCT) for EGFR-mutated NSCLCs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Neoadjuvant Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 41559619
DOI: 10.1186/s12885-026-15582-6
PMCID: PMC12908336

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.PMID 41559619Read ↗

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.Semantic proximity Read ↗

[Potential Value of Neoadjuvant Immunochemotherapy in Patients with Driver Gene-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: a meta-analysisSemantic proximity Read ↗

[Advances in neoadjuvant therapy for EGFR-mutant non-small cell lung cancer].Semantic proximity Read ↗

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.Semantic proximity Read ↗

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.Semantic proximity Read ↗

[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].Semantic proximity Read ↗

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.Semantic proximity Read ↗

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.Semantic proximity Read ↗

Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Semantic proximity Read ↗

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.